Celltrion's CT-P59 (regdanvimab) Receives CHMP's Positive Opinion for the Treatment of COVID-19
Shots:
- The EMA's CHMP has issued a positive opinion recommending the marketing authorization for regdanvimab (CT-P59) in adults with COVID-19 who do not require supplemental oxygen & are at increased risk of progressing to severe COVID-19
- The CHMP opinion was based on the P-III clinical trial to evaluate the efficacy and safety of regdanvimab in 1315+ patients with COVID-19 across 13 countries including the US, Spain & Romania. The results showed a 72% reduction in the risk of COVID-19 related hospitalization or death in high-risk patients
- The company has recently reported the development of a neutralizing Ab cocktail in combination with CT-P59 against new emerging variants of SARS-CoV-2
/ article Ref: Businesswire | Image: The Korea Economic Daily
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
